Melanotan II (MT-II)

Phase 2Small molecule

HHudson Biotech

Melanotan II (MT-II) is one of 36 small molecule programs targeting Vitiligo. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VitiligoActive, not recruiting

VitiligoPhase 2

Active, not recruiting

Competition

Competitive Landscape

103 competitors in Vitiligo

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

3 2

Opzelura

Pfizer

Phase 3

2 3

Prograf

VVeloxis Pharmaceuticals

Phase 3

8 4

Povorcitinib

Incyte

Phase 3

2 5

Olumiant

Eli Lilly

Phase 2

3 6

Saphnelo

AstraZeneca

Phase 2

1 7

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 9

Zocor

OOrganon and Co

Phase 2

1 10

Enbrel

IImmunex

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Vitiligo

NCT07437560

Clinical

Trials by Indication[1]

Vitiligo1 trial

Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo

Recruiting·HHudson Biotech·Phase 2·NCT07437560·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Melanotan II (MT-II). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Melanotan II (MT-II) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Melanotan II (MT-II). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hudson Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHudson Biotech

Melanotan II (MT-II)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Vitiligo1 trial

References

Drug Info

Quick Facts

Related News